GUCY2C

GUCY2C Overview

English NameHeat-stable enterotoxin receptorApproved Drugs1
Drugs in Clinical Trials9Target SynonymGUC2C,Intestinal guanylate cyclase,hSTAR,EC:4.6.1.2,EC 4.6.1,GC-C,GUCY2C,Guanylate Cyclase 2C,STA Receptor,Guanylyl Cyclase C,Guanylate Cyclase 2C (Heat Stable Enterotoxin Receptor),Heat-Stable Enterotoxin Receptor,STAR,Heat Stable Enterotoxin Receptor,EC 4.6.1.2,DIAR6,MECIL,MUCIL
Highest Development StageApproved
English NameHeat-stable enterotoxin receptor
Target SynonymGUC2C,Intestinal guanylate cyclase,hSTAR,EC:4.6.1.2,EC 4.6.1,GC-C,GUCY2C,Guanylate Cyclase 2C,STA Receptor,Guanylyl Cyclase C,Guanylate Cyclase 2C (Heat Stable Enterotoxin Receptor),Heat-Stable Enterotoxin Receptor,STAR,Heat Stable Enterotoxin Receptor,EC 4.6.1.2,DIAR6,MECIL,MUCIL
Approved Drugs1
Drugs in Clinical Trials9
Highest Development StageApproved

GUCY2C Background

GUCY2C (Guanylyl Cyclase C), also known as heat-stable enterotoxin receptor, is a type I transmembrane protein of the guanylate cyclase (gc) family that signal by producing cGMP. Guanylate cyclase C (GUCY2C) and its hormones guanylin and uroguanylin have recently emerged as one paracrine axis defending intestinal mucosal integrity against mutational, chemical, and inflammatory injury. GUCY2C murine CAR-T cells recognized and killed human colorectal cancer cells endogenously expressing GUCY2C. Thus, we have identified a human GUCY2C-specific CAR-T cell therapy approach that may be developed for the treatment of GUCY2C-expressing metastatic colorectal cancer.

GUCY2C Synonyms

GUCY2C,GUC2C,STAR,STA receptor,hSTAR,GC-C

Project Cooperation

Project NameDrug TypeTherapeutic AreaIndicationStageRights Area
Anti-GCC humanized antibodyBispecific antibodyOncology/CancerSolid TumorPreclinicalGlobal

Clinical Drug Information

English NameResearch CodeHighest Development StageCompanyIndicationClinical Trial
anti-GUCY2C CAR T-cell therapy (Parasol Biotechnology/Anhui provincial cancer hospital)Phase 1 ClinicalHeFei Parasol Biotech Co LtdColorectal Neoplasms
Details
anti-guanylyl cyclase C CAR-T cell therapy (Legend Biotech)LCAR-G08TPhase 1 ClinicalLegend Biotech CorpColorectal Neoplasms; Gastrointestinal Neoplasms
Details
HD-006HD006; HD-006Phase 1 ClinicalHuadao (Shanghai) Biopharma Co LtdSolid tumours
Details
REVO-UWD-01REVO-UWD-01; WD 01Phase 1 ClinicalWondercel Therapeutics Co LtdColorectal Neoplasms
Details
IM96 CAR-T cell TherapyIM96Phase 1 ClinicalImunopharm Technology Co LtdColorectal Neoplasms; Digestive System Neoplasms; Esophageal Neoplasms; Gastroesophageal Junction Neoplasms; Pancreatic Neoplasms; Solid tumours; Stomach Neoplasms
Details
GCC19CARTGCC19CART; LYL273; LYL-273Phase 1 ClinicalInnovative Cellular Therapeutics Co LtdColorectal Neoplasms; Rectal Neoplasms
Details
Gucy2c cart cell therapy (Innovative Cellular Therapeutics)Phase 1 ClinicalInnovative Cellular Therapeutics Co LtdDigestive System Neoplasms
Details
XKDCT-080XKDCT-080ClinicalThe Affiliated Hospital Of Qingdao UniversityColonic Neoplasms; Solid tumours
Details
CT-080CT-080ClinicalShenzhen Celconta Life Science Co LtdSolid tumours
Details

Marketed Drug Information

English NameResearch CodeHighest Development StageCompanyFirst Brand NameFirst Approved CountryFirst IndicationFirst Approved CompanyFirst Approved DateIndicationClinical Trial
PlecanatideSP-304; GCRAApprovedSynergy Pharmaceuticals IncTrulanceUnited StatesConstipation; Chronic idiopathic constipationSalix Pharmaceuticals2017-01-19Chronic idiopathic constipation; Constipation; Irritable Bowel Syndrome
Details
  • Overview
  • Product List
  • Marketed Drug Information
  • Clinical Drug Information